TherapySelect is a biotech and medtech company located in Heidelberg, which belongs to the biotechnology cluster Rhein-Neckar. Its focus is development, clinical validation, marketing and sales of diagnostic tests for cancer patients. The company’s aim is to increase patient’s survival and quality of life as well as to reduce costs in health care system. TherapySelect has three main areas of activity; the development and sales of its own or licensed products, distribution of other diagnostic tests and offering its diagnostic platforms to pharmaceutical companies for product development. Its main diagnostic products are its chemotherapy-resistance-test (CTR-Test®) and Caris Molecular Intelligence® services.